BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

929 related articles for article (PubMed ID: 11724929)

  • 1. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
    Du Y; Ma Z; Lin S; Dodel RC; Gao F; Bales KR; Triarhou LC; Chernet E; Perry KW; Nelson DL; Luecke S; Phebus LA; Bymaster FP; Paul SM
    Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14669-74. PubMed ID: 11724929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
    Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
    J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
    Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
    Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration.
    Fontanilla CV; Ma Z; Wei X; Klotsche J; Zhao L; Wisniowski P; Dodel RC; Farlow MR; Oertel WH; Du Y
    Neuroscience; 2011 Aug; 188():135-41. PubMed ID: 21571045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.
    Chung YC; Kim SR; Park JY; Chung ES; Park KW; Won SY; Bok E; Jin M; Park ES; Yoon SH; Ko HW; Kim YS; Jin BK
    Neuropharmacology; 2011 May; 60(6):963-74. PubMed ID: 21288472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minocycline enhances MPTP toxicity to dopaminergic neurons.
    Yang L; Sugama S; Chirichigno JW; Gregorio J; Lorenzl S; Shin DH; Browne SE; Shimizu Y; Joh TH; Beal MF; Albers DS
    J Neurosci Res; 2003 Oct; 74(2):278-85. PubMed ID: 14515357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
    Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
    Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
    Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
    Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
    Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
    FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.
    Ren B; Zhang YX; Zhou HX; Sun FW; Zhang ZF; Wei Z; Zhang CY; Si DW
    J Neurol Sci; 2015 Jan; 348(1-2):142-52. PubMed ID: 25491263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
    Delgado M; Ganea D
    FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons.
    Lin S; Zhang Y; Dodel R; Farlow MR; Paul SM; Du Y
    Neurosci Lett; 2001 Nov; 315(1-2):61-4. PubMed ID: 11711215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
    Yokoyama H; Takagi S; Watanabe Y; Kato H; Araki T
    J Neural Transm (Vienna); 2008 Jun; 115(6):831-42. PubMed ID: 18235988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
    Watanabe H; Muramatsu Y; Kurosaki R; Michimata M; Matsubara M; Imai Y; Araki T
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):93-104. PubMed ID: 15013024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
    Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
    J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
    J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice.
    Yokoyama H; Yano R; Aoki E; Kato H; Araki T
    Metab Brain Dis; 2008 Sep; 23(3):335-49. PubMed ID: 18648914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.